Michael Wilschanski

Michael Wilschanski

Auto-generated profile, based on publicly available information

Michael Wilschanski

Department of Pediatrics, Hadassah—Hebrew University Medical Center, Jerusalem 9112001, Israel

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Clinical Nutrition
Verified
Journal Article
Closed access
DTDominique Turck
Dominique Turck
CBChristian P. Braegger
Christian P. Braegger
CCCarla Colombo
Carla Colombo
DDDimitri Declercq
Dimitri Declercq
AMAlison Morton
Alison Morton
MWMichael Wilschanski
Michael Wilschanski

13 January 2011 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MWM. Wilschanski
M. Wilschanski
LML.L. Miller
L.L. Miller
DSD. Shoseyov
D. Shoseyov
HBH. Blau
H. Blau
JRJ. Rivlin
J. Rivlin
EKE. Kerem
E. Kerem
In a subset of patients with cystic fibrosis (CF), nonsense mutations (premature stop codons) disrupt production of full-length, functional CF transmembrane conductance regulator (CFTR). Ataluren (PTC124) allows ribosomal readthrough of premature stop codons in mRNA.We evaluated drug activity and safety in patients with nonsense mutation CF who took ataluren three times daily (morning, midday and evening) for 12 weeks at either a lower dose (4, 4 and 8 mg·kg−1) or higher dose (10, 10 and 20 mg·kg−1).The study enrolled 19 patients (10 males and nine females aged 19–57 yrs; dose: lower 12, higher seven) with a classic CF phenotype, at least one CFTR nonsense mutation allele, and an abnormal nasal total chloride transport. Both ataluren doses were similarly active, improving total chloride transport with a combined mean change of -5.4 mV (p<0.001), and on-treatment responses (at least -5 mV improvement) and hyperpolarisations (values more electrically negative than -5 mV) in 61% (p<0.001) and 56% (p = 0.002) of patients. CFTR function was greater with time and was accompanied by trends toward improvements in pulmonary function and CF-related coughing. Adverse clinical and laboratory findings were uncommon and usually mild.Chronic ataluren administration produced time-dependent improvements in CFTR activity and clinical parameters with generally good tolerability.

27 December 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
MWMichael Wilschanski
Michael Wilschanski
AMAnne Munck
Anne Munck
ECEstefania Carrion
Estefania Carrion
MCmarco cipolli
marco cipolli
SCSarah Collins
Sarah Collins
MCMichael Chourdakis
Michael Chourdakis

16 January 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
PNEUMOLOGIE BurgelPNEUMOLOGIE Burgel
PNEUMOLOGIE Burgel
KSKevin Southern
Kevin Southern
CACharlotte Addy
Charlotte Addy
ABAlberto Battezzati
Alberto Battezzati
CBClaire Berry
Claire Berry
PMPeter Middleton
Peter Middleton
This is the third in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on recognising and addressing CF health issues. The guidance was produced with wide stakeholder engagement, including people from the CF community, using an evidence-based framework. Authors contributed sections, and summary statements which were reviewed by a Delphi consultation. Monitoring and treating airway infection, inflammation and pulmonary exacerbations remains important, despite the widespread availability of CFTR modulators and their accompanying health improvements. Extrapulmonary CF-specific health issues persist, such as diabetes, liver disease, bone disease, stones and other renal issues, and intestinal obstruction. These health issues require multidisciplinary care with input from the relevant specialists. Cancer is more common in people with CF compared to the general population, and requires regular screening. The CF life journey requires mental and emotional adaptation to psychosocial and physical challenges, with support from the CF team and the CF psychologist. This is particularly important when life gets challenging, with disease progression requiring increased treatments, breathing support and potentially transplantation. Planning for end of life remains a necessary aspect of care and should be discussed openly, honestly, with sensitivity and compassion for the person with CF and their family. CF teams should proactively recognise and address CF-specific health issues, and support mental and emotional wellbeing while accompanying people with CF and their families on their life journey.

7 August 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
DBDrucy Borowitz
Drucy Borowitz
BLBarry Lubarsky
Barry Lubarsky
MWMichael Wilschanski
Michael Wilschanski
AMAnne Munck
Anne Munck
DGDaniel Gelfond
Daniel Gelfond
SSSarah Jane Schwarzenberg
Sarah Jane Schwarzenberg

1 September 2014 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
VMVeronique D. Morinville
Veronique D. Morinville
MLMark E. Lowe
Mark E. Lowe
MAMonika Ahuja
Monika Ahuja
BBBradley Barth
Bradley Barth
MBMelena D. Bellin
Melena D. Bellin
AUAliye Uc
Aliye Uc
Objectives: Acute recurrent pancreatitis (ARP) and chronic pancreatitis (CP) are rare and poorly understood diseases in children. Better understanding of these disorders can only be accomplished via a multicenter, structured, data collection approach.Methods: The International Study Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE) consortium was created to investigate the epidemiology, etiologies, pathogenesis, natural history, and outcomes of pediatric ARP and CP. Patient and physician questionnaires were developed to capture information on demographics, medical history, family and social history, medications, hospitalizations, risk factors, diagnostic evaluation, treatments, and outcome information. Information collected in paper questionnaires was then transferred into Research Electronic Data Capture (REDCap), tabulated, and analyzed.Results: The administrative structure of the INSPPIRE consortium was established, and National Institutes of Health funding was obtained. A total of 14 sites (10 in the United States, 2 in Canada, and 2 overseas) participated. Questionnaires were amended and updated as necessary, followed by changes made into the REDCap database. Between September 1, 2012 and August 31, 2013, a total of 194 children were enrolled into the study: 54% were girls, 82% were non‐Hispanic, and 72% were whites.Conclusions: The INSPPIRE consortium demonstrates the feasibility of building a multicenter patient registry to study the rare pediatric diseases, ARP and CP. Analyses of collected data will provide a greater understanding of pediatric pancreatitis and create opportunities for therapeutic interventional studies that would not otherwise be possible without a multicenter approach.